161 related articles for article (PubMed ID: 36068950)
21. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
Front Immunol; 2022; 13():969660. PubMed ID: 36059523
[TBL] [Abstract][Full Text] [Related]
22. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss.
Furqan F; Shah NN
Annu Rev Med; 2023 Jan; 74():279-291. PubMed ID: 36332638
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Fu S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y; Cao J; Gu W; Shi M; Lan J; Yan Z; Jin L; Xia J; Ma S; Liu Y; Li H; Pan B; Chen W; Fei X; Wang C; Xie X; Yu L; Wang G; Li H; Jing G; Cheng H; Zhu F; Sun H; Sang W; Li D; Li Z; Zheng J; Xu K
J Clin Oncol; 2022 Jul; 40(20):2246-2256. PubMed ID: 35333600
[TBL] [Abstract][Full Text] [Related]
25. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Zurko J; Nizamuddin I; Epperla N; David K; Cohen JB; Moyo TK; Ollila T; Hess B; Roy I; Ferdman R; Liu J; Chowdhury SM; Romancik J; Bhansali RS; Harris EI; Sorrell M; Masel R; Kittai AS; Denlinger N; Sigmund AM; Fitzgerald L; Galvez C; Ma S; Winter J; Pro B; Gordon LI; Danilov A; Stephens D; Shah NN; Kenkre V; Barta SK; Torka P; Shouse G; Karmali R
Blood Adv; 2023 Jun; 7(12):2657-2669. PubMed ID: 36094847
[TBL] [Abstract][Full Text] [Related]
26. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
27. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
[TBL] [Abstract][Full Text] [Related]
28. Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.
Yu Q; Zhang X; Wang N; Li C; Zhang Y; Zhou J; Wang G; Cao Y
Radiother Oncol; 2022 Dec; 177():53-60. PubMed ID: 36309153
[TBL] [Abstract][Full Text] [Related]
29. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
[TBL] [Abstract][Full Text] [Related]
30. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma.
Voorhees TJ; Zhao B; Oldan J; Hucks G; Khandani A; Dittus C; Smith J; Morrison JK; Cheng CJ; Ivanova A; Park S; Shea TC; Beaven AW; Dotti G; Serody J; Savoldo B; Grover N
Blood Adv; 2022 Feb; 6(4):1255-1263. PubMed ID: 34666347
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
32. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma.
Huang L; Li J; Yang J; Zhang X; Zhang M; He J; Zhang G; Li W; Wang H; Li J; Lu P
Cells; 2022 Dec; 11(24):. PubMed ID: 36552849
[TBL] [Abstract][Full Text] [Related]
34. A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
Zhang Y; Li J; Lou X; Chen X; Yu Z; Kang L; Chen J; Zhou J; Zong X; Yang Z; Li M; Xu N; Jia S; Geng H; Chen G; Dai H; Tang X; Yu L; Wu D; Li C
Front Oncol; 2021; 11():664421. PubMed ID: 34113569
[TBL] [Abstract][Full Text] [Related]
35. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
36. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
37. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G; Navarro V; Martín-López AÁ; Rejeski K; Kwon M; Jalowiec KA; Amat P; Reguera-Ortega JL; Gallur L; Blumenberg V; Gutiérrez-Herrero S; Roddie C; Benzaquén A; Delgado-Serrano J; Sánchez-Salinas MA; Bailén R; Carpio C; López-Corral L; Hernani R; Bastos M; O'Reilly M; Martín-Martín L; Subklewe M; Barba P
J Clin Oncol; 2024 Jan; 42(2):205-217. PubMed ID: 37874957
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
Di Blasi R; Le Gouill S; Bachy E; Cartron G; Beauvais D; Le Bras F; Gros FX; Choquet S; Bories P; Feugier P; Casasnovas O; Bay JO; Mohty M; Joris M; Gastinne T; Sesques P; Tudesq JJ; Vercellino L; Morschhauser F; Gat E; Broussais F; Houot R; Thieblemont C
Blood; 2022 Dec; 140(24):2584-2593. PubMed ID: 36122385
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]